Viral Vector-Based Melanoma Gene Therapy

Area of Science:

• Oncology
• Virology
• Gene Therapy

Background:

• Oncolytic viruses are explored as an alternative cancer treatment strategy.
• Various viral vectors (adenoviruses, herpes simplex viruses, etc.) have been studied in preclinical and clinical settings for diverse cancers.
• Current research emphasizes immunotherapy, with approved viral vector-based drugs, yet melanoma applications remain underdeveloped.

Purpose of the Study:

• To review the achievements of preclinical and clinical studies utilizing viral vectors for cancer gene therapy.
• To specifically focus on the application and potential of viral vectors in treating malignant melanoma.

Main Methods:

• Literature review of preclinical and clinical studies on oncolytic viruses.
• Analysis of viral vector applications across various cancer types.
• Focused examination of studies pertaining to malignant melanoma.

Main Results:

• Oncolytic viruses have demonstrated efficacy in treating various cancers like colon, head-and-neck, prostate, breast cancer, squamous cell carcinoma, and glioma.
• Several viral vector-based drugs have gained approval, primarily for immunotherapy applications.
• Malignant melanoma has not yet fully benefited from gene therapy approaches using viral vectors.

Conclusions:

• Oncolytic virus gene therapy holds significant potential for cancer treatment.
• Further research and development are needed to fully exploit viral vector applications for malignant melanoma.
• This review highlights the progress and future directions for oncolytic virotherapy in melanoma.